Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia

Oncologist

Volumn 6, Issue SUPPL. 2, 2001, Pages 11-16

  Soignet, Steven L ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; CHINA; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; PRIORITY JOURNAL; REMISSION; SALVAGE THERAPY;

EID: 0035040975     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_2-11     Document Type: Conference Paper

References (41)

1. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
2. Acute promyelocytic leukemia
3. Acute promyelocytic leukemia: Biology and treatment
4. Annexin II and bleeding in acute promyelocytic leukemia
5. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia
6. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
7. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia
8. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia
9. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML
10. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus
11. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17
12. Acute promyelocytic leukemia
13. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): Results of the European Working Party
14. Retinoid receptors in development and disease
15. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
16. The molecular biology of acute promyelocytic leukemia
17. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia
18. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid
19. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
20. Differentiating therapy in acute myeloid leukemia
21. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study
22. Current issues in the management of acute promyelocytic leukemia
23. All-trans-retinoic acid in acute promyelocytic leukemia
24. Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group
25. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
26. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups
27. Current issues in the management of acute promyelocytic leukemia
28. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation
29. Heavy metals and heavy-metal antagonists
30. Delicious poison: Arsenic trioxide for the treatment of leukemia
31. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia
32. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
33. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
34. Arsenic trioxide, a novel mitochondriotoxic anticancer agent?
35. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
36. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
37. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
38. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis
39. U.S. multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL)
40. Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): The combined results and follow-up from the U.S. pilot and multicenter trials
41. The "retinoic acid syndrome" in acute promyelocytic leukemia